Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury by Russell, Clark D et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical evidence does not support corticosteroid treatment for
2019-nCoV lung injury
Citation for published version:
Russell, CD, Millar, JE & Baillie, JK 2020, 'Clinical evidence does not support corticosteroid treatment for
2019-nCoV lung injury', The Lancet, vol. 395, no. 10223, pp. 473-475. https://doi.org/10.1016/S0140-
6736(20)30317-2
Digital Object Identifier (DOI):
10.1016/S0140-6736(20)30317-2
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
The Lancet
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 22. Sep. 2020
Clinical evidence does not support corticosteroid
treatment for 2019-nCoV lung injury
Clark D. Russell, Jonathan E. Millar, J. Kenneth Baillie
The 2019-nCoV outbreak
The 2019 novel coronavirus (2019-nCoV) outbreak represents a major challenge
for clinicians: the clinical course of patients remains to be fully characterised,
there is little data describing disease pathogenesis, and there are no pharmaco-
logical therapies of proven efficacy.
Corticosteroids were widely used during the SARS-CoV1 and MERS-CoV2
outbreaks, and are presently being used in patients with 2019-nCoV.3 However,
current guidance from WHO advises against the use of corticosteroids unless
indicated for another reason.4 Understanding the evidence for harm or benefit
from corticosteroids in 2019-nCoV is of immediate clinical importance.
Rationale for corticosteroid therapy
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are, in
part, driven by host immune responses. Corticosteroids suppress lung inflamma-
tion, but also inhibit immune responses and pathogen clearance. In severe acute
respiratory syndrome coronavirus (SARS-CoV) infection, as with influenza, sys-
temic inflammation is associated with adverse outcomes.5 In SARS, inflammation
persisted after viral clearance.6,7 Pulmonary histology in both SARS and Middle
Eastern respiratory syndrome (MERS-CoV) infection reveals inflammation and
diffuse alveolar damage8 with one report suggesting haemophagocytosis.9 There
is a theoretical role for corticosteroid treatment to suppress lung inflammation.
Clinical evidence in respiratory viral infection
Emerging coronaviruses (SARS-CoV and MERS-CoV)
In a retrospective observational study reporting on 309 critically-ill adults with
MERS,2 almost half of patients (49%) received corticosteroids (median hydro-
cortisone equivalent dose*= 300mg/day). Patients receiving corticosteroids were
more likely to require mechanical ventilation, vasopressors, and renal replacement
therapy. After statistical correction for immortal time and indication biases, the
authors concluded that corticosteroid administration was not associated with a
difference in 90-day mortality (adjusted OR 0.8, 95% CI 0.5-1.1, p=0.1) but was
associated with delayed clearance of viral RNA from respiratory tract secretions
(adjusted HR 0.4, 95% CI 0.2-0.7, p=0.0005). However, these effect estimates
carry a high risk of error due to the likely presence of unmeasured confounders.
In a meta-analysis of corticosteroid use in patients with SARS, only four studies
provided conclusive data, all indicating harm.1 In a case-control study of SARS
1
patients with (n=15) and without (n=30) SARS-related psychosis, all received
corticosteroid treatment but those developing psychosis received a higher cu-
mulative dose (10,975mg hydrocortisone equivalent vs. 6780mg, p=0.02).10 In a
randomised controlled trial of 16 patients with SARS, who were not critically ill,
the nine patients receiving hydrocortisone (mean 4.8 days from fever onset) had
greater viraemia in the second and third week post-infection.11 The remaining
two studies, from the Chinese literature, reported diabetes and avascular necrosis
as complications associated with corticosteroid treatment.12,13
Influenza virus
A recent systematic review and meta-analysis14 identified 10 observational
studies in influenza, with a total of 6548 patients. There was a signal for
increased mortality in patients receiving corticosteroids (RR 1.75, 95% CI 1.3-
2.4, p=0.0002). Among other outcomes, ICU length of stay was increased (MD
2.1, 95% CI 1.2-3.1, p<0.0001), as was the rate of secondary bacterial or fungal
infection (RR 2.0, 95% CI 1.0-3.8, p=0.04).
Respiratory syncytial virus
Corticosteroids have been investigated for RSV in clinical trials, with no conclu-
sive evidence of benefit, and are therefore not recommended.15 An observational
study of 50 adults with RSV infection, in which 66% received corticosteroids,
found a trend towards impaired antibody responses at 28 days in those given
corticosteroids.16
Table 1: Summary of clinical evidence
Virus Outcome of corticosteroid therapy Reference
MERS-CoV Delayed clearance of viral RNA from
respiratory tract
2
SARS-CoV Delayed clearance of viral RNA from
blood
11
SARS-CoV Complication: psychosis 10
SARS-CoV Complication: diabetes 12
SARS-CoV Complication: avascular necrosis in
survivors
13
Influenza Increased mortality 14
RSV No immunological benefit in adults 16
RSV No clinical benefit in children 15
2
Clinical evidence in critical illness
ARDS
Life-threatening ARDS occurs in 2019-nCoV infection.17 However, because trials
in ARDS typically include a majority of patients with ARDS of nonpulmonary
or sterile aetiology, generalising evidence from ARDS studies to viral lung injury
is problematic. A recent review of treatments for ARDS of any aetiology, based
on 6 studies with a total of 574 patients,18 concluded that there is insufficient
evidence to recommend their use.19
Septic shock
Septic shock has been reported in 4% of patients with 2019-nCoV.17 Corticos-
teroids are widely used in septic shock despite uncertainty over efficacy. The
vast majority of patients in septic shock trials have bacterial infection, leading
to vasoplegic shock and myocardial insufficiency.20,21 In this group, there is
a trend towards benefit from steroid treatment in severe shock.20,21 However,
shock in severe hypoxaemic respiratory failure is often a consequence of raised
intrathoracic pressure (during invasive ventilation) impeding cardiac filling, and
not vasoplegia.22 In this context it is unlikely that steroid treatment will provide
benefit.
Conclusions
There is no clinical data to indicate that net benefit is derived from corticosteroids
in the treatment of respiratory infection due to RSV, influenza, SARS-, or MERS-
CoV. The available observational data suggest increased mortality and secondary
infection rates in influenza, impaired clearance of SARS- and MERS-CoV, and
complications of corticosteroid therapy in survivors. If it is present, the effect of
steroids on mortality in septic shock is small, and is unlikely to be generalisable
to shock in the context of severe respiratory failure due to 2019-nCoV.
Overall, there is no unique reason to expect that patients with 2019-nCoV
infection will benefit from corticosteroids, and they may be more likely to suffer
harm. We conclude that corticosteroids should not be used in 2019-nCoV
outside of a clinical trial, unless there is another clinical reason for corticosteroid
treatment.
* Hydrocortisone-equivalent doses (methylprednisolone 1:5, dexamethasone 1:25,
prednisolone 1:4)
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